Introduction
Insulin-like growth factor-I (IGF-I) has been shown to be an important anabolic cytokine in cartilage repair. [1] [2] [3] Numerous studies in various animal models have defined the beneficial effects of IGF-I, which include increased cell survival and improved matrix quality through anabolic effects on proteoglycan synthesis and increased type II collagen production. 2, [4] [5] [6] [7] [8] [9] [10] Despite these obvious contributions to the mechanisms of cartilage repair, it has been shown that constitutive IGF-I expression levels fluctuate in healing cartilage, and expression is minimal at 2 and 16 weeks following cartilage injury. 11 These periods of reduced IGF-I level may contribute to the poor quality of intrinsic repair. 11 Of the cytokines known to control cartilage development and homeostasis, IGF-I has emerged as one of the most critical growth factors for cartilage repair. 12 Various in vitro studies have reported augmented chondrocyte activity in cultures exposed to IGF-I. 1, 2 Furthermore, IGF-I has improved cartilage healing in vivo when chondrocytes are combined with IGF-I and transplanted into large osteochondral defects. 13 To that end, long-term IGF-I supplementation in procedures such as autologous chondrocyte transplantation may improve chondrocyte survival and enhance matrix synthesis, resulting in improved overall cartilage repair. However, the longevity of IGF-I ligand persistence in biological systems remains a limiting factor in exogenous supplementation, 13, 14 and has necessitated either high initial doses or repeat treatments. 4, 15 Gene therapy presents a novel and effective way to extend delivery of important anabolic peptides like IGF-I to cells such as chondrocytes and synoviocytes. The goal is to transfer genes encoding therapeutic molecules to intra-articular tissues, so that they may then become endogenous sites for therapeutic protein synthesis. Delivery of IGF-I through a gene-mediated protocol focuses on stimulating an anabolic response in the synovial tissues that may then impact on cartilage repair and synovial tissue synthetic functions. This is in contrast to the delivery of the interleukin-1 receptor antagonist (IL-1Ra) gene that has been effective in controlling the cartilage catabolic response to injury. 16 Previous reports of gene therapy approaches in joints describe retroviral vectors containing the IL-1Ra gene. 17, 18 However, synoviocytes in situ are poorly mitotic, which limits retroviral transduction efficiencies and necessitates the cells to be transduced with retrovirus ex vivo and re-injected to successfully establish genetically modified cells. In contrast, the adenoviral vector does not require mitosis to successfully transduce cells in situ, and synoviocytes are easily transduced by this vector. 16, [19] [20] [21] However, the potential drawbacks associated with adenoviral vectors include the inflammatory response that they invoke in various tissues and the episomal location of transgenic DNA, which precludes the gene of interest being expressed long-term. 19 Although chondrocytes in monolayer are receptive to the transfer of growth factor genes, their protected position in the matrix in vivo impedes gene transfer to cells. 9, 22, 23 This makes the synovium a logical choice for in situ genetic modification. Synoviocytes are in close proximity to chondrocytes in cartilage and the synovial fluid allows the expressed protein immediate availability to cartilage.
In vitro studies suggest that synoviocytes in monolayer and explant cultures can be successfully transduced with adenoviral IGF-I (AdIGF-I), resulting in significant elevations of IGF-I in the medium. 24 The purposes of this study were (1) to confirm that the AdIGF-I vector could transduce synovial cells in situ and result in significant elevations in IGF-I levels in the synovial fluid and synovial tissues; (2) to establish what AdIGF-I viral particle (vp) dose was needed to achieve significant synovial IGF-I elevations; (3) to examine the effects of transgene expression in synovium; and (4) to determine if any deleterious effects on the synovium or cartilage were associated with injection of the adenoviral constructs. We hypothesized that the AdIGF-I construct would transduce the synovial tissues with high efficiency, result in dose-escalating elevations of IGF-I ligand and result in minimal detrimental effects owing to the transgene or the adenovirus vector portion of the AdIGF-I construct.
The equine carpal, metacarpophalangeal (MCP) and femorotibial joints have distinct advantages when used as models for joint physiology and arthritis research, including large-scale joints with several milliliters of synovial fluid, 2-3 mm thick cartilage, ready accessibility for arthroscopic examination, significant synovial surface area and similar synovial architecture to the high motion joints in man. [25] [26] [27] [28] [29] [30] To the best of our knowledge, this is the first study to determine if significant elevations of growth factors can be achieved by direct in situ genetic modification of synovial tissues and to assess what impact these growth factor fluxes have on synovial membrane and cartilage morphology in a large animal joint model assessed over a 35-day period.
Results
Insulin-like growth factor-I ligand synthesis Radioimmunoassay for Insulin-like growth factor-I.
Synovial IGF-I ligand fluxes following increasing AdIGF-I particle doses from 1 Â 10 10 to 50 Â 10 10 administered by direct injection into the MCP joints of 14 horses were assessed by radioimmunoassay. Synovial fluid IGF-I ligand content (Figure 1 ) was significantly increased in the joints of horses that received the highest AdIGF-I construct dose (50 Â 10 10 vp) with the highest dose having an average maximum difference of 48.8 ng/ ml719.6 (standard deviation). Figure 1 depicts mean synovial IGF-I content over time until arthroscopic scoring and biopsy on day 35 for joints receiving varying AdIGF-I doses. Ligand levels are also presented as maximum peak change in levels for each dose (Table  1) , determined by the difference in IGF-I levels between day 0 and the maximum level achieved during the 35 day post-treatment period. Synovial fluid IGF-I content was significantly higher in joints injected with 50 Â 10 10 vp compared to joints receiving saline, AdLacZ and the lowest dose of AdIGF-I (1 Â 10 10 vp). Most joints in each dose group had the maximum change at day 3 or 7 postinjection (Figure 1 ). Additionally, to gauge the IGF-I ligand accumulation differences over the entire 35-day period, ligand production was compared using the area under the curve for each dose from day 0 to 35. Using this method, the highest AdIGF-I dose (50 Â 10 10 vp) resulted in significantly higher IGF-I than joints receiving saline, AdLacZ or the lowest dose of AdIGF-I (Table 1) .
Insulin-like growth factor-I mRNA expression and persistence Real-time PCR. Synovial membrane IGF-I message expression following increasing AdIGF-I particle doses from 1 Â 10 10 to 50 Â 10 10 administered into the MCP joints was assessed by Taqman real-time PCR of mRNA from synovial tissue harvested on day 0 and 35. Change in IGF-I mRNA levels was greatest in joints receiving the highest dose of AdIGF-I. However, this increase was not Table 2 .
Insulin-like growth factor-I in situ hybridization. The change in IGF-I mRNA hybridization intensity scores between synovial tissue harvested pretreatment and at day 35 was calculated for each joint, and mean differences for each AdIGF-I dose were compared. Synovial tissue from joints of horses receiving the two highest doses of AdIGF-I had a greater increase in message intensity (Pp0.05) (Figure 2 ). This elevation in IGF-I signal intensity was located primarily in the intimal layer of the synovial membrane within these joints.
In situ hybridization for IGF-I message intensity was similar for cartilage from joints of all horses. Cartilage proteoglycan content. Proteoglycan levels of cartilage harvested from joints at day 35 are presented in Table 3 , and were similar between groups. There were no significant differences between groups.
Synovial histology. The differences in synovial scores between pretreatment and post-treatment were calculated for all joints. The total scores and subcategories were compared for all groups of joints. Total score change (Table 4) was not significantly different between groups. However, the synovial inflammation subcategory had a significantly higher change in score for the second highest dose group (AdIGF-I 20 Â 10 10 vp), compared to all other groups ( Figure 5 ). The highest dose group (AdIGF-I 50 Â 10 10 ) was not significantly different when compared to other groups.
Cartilage histology. Scores for cartilage histology were not significantly different for tissues from any of the dose groups (Table 5) . Synovial IGF-I gene-mediated joint stimulation LR Goodrich et al were above 50 ng/ml for as long as 3 weeks in joints transduced with the higher AdIGF-I doses. Previous data indicate that IGF-I levels of 50 ng/ml stimulate significant anabolic activity in cartilage and chondrocytes, 1, 10 and the implications for this in vivo study in the MCP joint include likely stimulus to cartilage homeostasis and potentially repair. IGF-I levels were measured by two different methods: the first analysis compared differences from pretreatment to maximum level attained, and the second compared accumulated ligand over 35 days. The data were assessed using both these methods, as peak levels were important as well as the duration of IGF-I elevation. Insulin-like growth factor-I levels in five out of six joints in the highest dosing group (50 Â 10 10 ) peaked on day 3. Area under the curve was calculated for each dosing group, and all calculations were normalized to the level at day 0 (for each group). This was necessary owing to Synovial IGF-I gene-mediated joint stimulation LR Goodrich et al moderate IGF-I ligand variability between groups on day 0 that appeared to be partly a result of lingering elevations of ligand from the pretreatment synovial biopsy harvested 14 days earlier.
The temporal patterns of IGF-I ligand elevations were similar to those seen in gene therapy studies using adenovirus in vitro. 24 In that study, synovial explants transduced with AdIGF-I secreted maximal protein levels on day 4. After day 4, ligand levels dropped to approximately one-fourth of maximal levels within 8 days, and the explants were then harvested. In a study by Mi et al., 8 an adenoviral vector construct expressing human IGF-I was injected into the knees of rabbits, and resulted in significant protein elevations on days 3 and 7, at which point all rabbits were killed. In Saxer et al's 24 in vitro study, and the in vitro portion of Mi's study in rabbits, the IGF-I levels were higher in tissue culture than in the rabbit joints or the equine MCP joints in the present study. 8, 24 This may be a reflection of the absence of IGF-I binding proteins in vitro, given that this system lacks viable chondrocytes or active circulation to bolster Figure 4 Total white blood cell counts for joints injected with saline, AdLacZ or AdIGF-I at various doses. Average white blood cell counts for joints injected with the two highest doses of AdIGF-I (20 Â 10 10 and 50 Â 10 10 ) showed a mild but significant transient elevation in white blood cell counts. Negative values represent scores that decreased between days 0 and 35. Scores at each time point ranged from 0 to 3 (0 ¼ no change, 3 ¼ severe). At each time point, scores were averages of two observers unaware of treatment group. Asterisk represents a significant difference between saline and treatment. 31, 32 Insulin-like growth factor-I has been shown to increase when binding protein proteolysis is inhibited. 33 Therefore, it is quite plausible that the presence of binding proteins reduces the response of AdIGF-I in the joint compared to the in vitro response. Although the IGF-I assay disassociates most binding proteins present in the synovial fluid, providing an accurate measure of total IGF-I, previous work suggests that IGF-I ligand bound to IGF-I binding proteins may be degraded more slowly over time or internalized in chondrocytes. 34 Furthermore, IGF-I actively enters the circulation in the live animal, particularly the unbound ligand, which may further reduce IGF-I levels in synovial fluid compared to culture medium.
Temporal declines in transgene activity over a period of 2-4 weeks have been observed in other studies utilizing adenovirus as a delivery vector. 9, 16, 35 Although this elevation would positively impact cartilage healing in the first 4 weeks and possibly longer, the need for vectors that express proteins for months rather than weeks may be indicated. New vectors, such as adenoassociated virus or lentiviral vectors, may fulfill that need and are currently under investigation. [36] [37] [38] In situ localization of IGF-I mRNA confirmed the active expression of the AdIGF-I transgene in synovial membrane cells. The levels of IGF-I mRNA in the synovium also tended to be greatest for the two highest doses. These data suggest that the two highest doses of AdIGF-I effectively transduced the synovial tissues after direct injection. The spatial distribution of IGF-I mRNA expression showed the most intense signal in the intimal layers of the synovial membrane, which would be exposed to the greatest viral load compared to deeper synovial subintimal and capsular layers.
Clinical examination of horses indicated that none of the joints injected with saline, AdIGF-I or AdLacZ became painful or developed significant joint fluid effusion. Joint effusion, lameness and sensitivity to flexion of the joint are good indicators of inflammation. 39, 40 An absence of lameness and effusion was also noted in another study that utilized an adenoviral vector construct to deliver an IL-IRa transgene to the carpal joints of horses. 16 Although the horses did not show clinical evidence of pain and/or inflammation, a mild elevation in total WBC count was observed in synovial fluid of the two groups of joints injected with the highest doses. This elevation was primarily owing to polymorphonuclear WBCs. In equine joints, normal WBC counts range from 4 to 600 and increase to 4000 cells/ml with repeated arthrocentesis. 41 The mean synovial WBC count rose to 8000 cells/ ml for the high-dose group (50 Â 10 10 vp) on day 14. This elevation is still considered mild in the equine joint. White blood cell elevations of this order were also seen in other studies where AdIGF-I and AdIL-IRa were injected. 8, 16 Histologic analysis revealed a mild mononuclear leukocyte infiltration of the synovial membrane. This inflammatory response was probably owing to the vector construct and not IGF-I, as the transgene was equine specific, and the reaction was evident in AdLacZ synovial tissue. Studies have shown that adenoviral constructs can induce inflammation when the vector is used at doses high enough to stimulate an immune reaction. [42] [43] [44] Adenoviral initiation of immune reaction is believed to be caused by the exclusion of the E1A and E1B segment from the adenoviral construct, which in the wild-type adenovirus are responsible for inhibiting the host cells immune reaction. 43 It is believed that E1A encodes the viral functions known to inhibit the earliest steps of the innate immune response to Ad, which normally results in the adenovirus causing only subclinical infections. 45 Adenoviral vectors are made replication defective by deleting the E1A, E1B and E3 portions of the DNA coding sequence. The E3 gene is also considered vital in defending the virus from the host's immune system. 43 Overexpression of E3 leads to enhanced vector function 46, 47 and reduced immune response. 43 The vector in the current study was E1A, E1B and E3 deleted, and the highest viral dose apparently exceeded the threshold required to initiate inflammation. Other studies using adenoviral vectors observed elevations in synovial fluid WBC counts. 8, 16 One of these studies observed an increase in perivascular lymphocytic infiltration, 16 whereas the other did not. 8 However, in the latter study, test subjects were euthanized only 7 days after injection. Although mild increases in synovial membrane leukocyte infiltration and synovial fluid total WBC counts were seen in the present study, synovial fluid protein content was not elevated for any joint.
Various cell types, such as skin fibroblasts, pericardium and epiphyseal chondrocytes, respond to IGF-I by upregulating hyaluronan synthesis. [48] [49] [50] However, this response was not detected in the present study nor was it detected during in vitro culture of IGF-I-transduced synovial tissue. 24 Most studies of articular gene therapy utilize an approach that inhibits catabolic proteins such as IL-1 and IL-10. 16, 36, 51 Although blocking the detrimental effects of the inflammatory cascade is a logical approach to managing arthritis, we believe that enhancing the , which represented an approximate dose of 50 Â 10 8 AdIGF-I transducing particles. This dose does not result in lameness or gross changes in the joint; however, mild transient WBC elevations develop in the synovial fluid and tissue. Horses appeared to tolerate injections well, with none exhibiting signs of lameness or effusion throughout the study. Given the benefits of significant elevations of IGF-I in synovial fluid, use of AdIGF-I may be indicated in treating joints with injured or damaged cartilage.
Materials and methods

Adenoviral vector production
The full-length coding sequence for equine IGF-I was cloned and sequenced. 52 First-generation E1E3-deleted adenovirus-5 vectors were used for the construct. Recombinant adenoviral vectors containing either the lac Z gene of Escherichia coli (AdLacZ) or an 888 bp segment of equine IGF-I cDNA (AdIGF-I) were constructed using cre-lox recombination, essentially as described by Hardy et al. 53 The IGF-I sequence coded the entire prepropeptide for equine IGF-I. Both viral constructs utilized the human cytomegalovirus early promoter to drive the transgene expression. The recombinant product was propagated in a transformed embryonic kidney cell line. Viral particles from lysed cells were purified by banding on two sequential cesium chloride step gradients. Salt was removed by dialysis in a sucrose-containing buffer. Total viral titer of stocks was determined spectrophotometrically, and an infectious titer was estimated to be 1% of this total.
In vivo joint injection
Fourteen horses ranging in age from 2 to 6 years old were used for this study. Horses were determined to be healthy and without lameness before beginning the study. All procedures were carried out with the approval of the Institutional Animal Care and Use Committee. Horses were sedated, local anesthesia of the skin over the MCP joint was performed and a small incision was made through skin and joint capsule. A synovial biopsy was then obtained using arthroscopic rongeurs. A skin suture was placed following the biopsy.
Fourteen days following synovial biopsy, a joint fluid aspirate was collected (day 0). AdIGF-I and AdLacZ were thawed and diluted in phosphate-buffered saline to 2 ml. Two milliliter of either a virus preparation or saline was injected into a forelimb MCP joint. Horses were randomly assigned into one of six groups. Group 1 had saline injected into each front MCP joint, group 2 had 20 Â 10 10 vp of AdLacZ injected, group 3, 4, 5 and 6 had AdIGF-I injected in increasing doses of 1 Â 10 10 , 10 Â 10 10 , 20 Â 10 10 and 50 Â 10 10 vp, respectively. Each group had a total of four joints except groups 5 and 6 where each group contained six joints.
Following injection of saline, AdIGF-I or AdLacZ, synovial fluid (1-2 ml) from each injected joint was collected (by needle aspiration) on days 3, 7, 14, 21, 28 and 35. On day 35, horses were anesthetized and positioned in dorsal recumbency, and both forelimb MCP joints prepared for aseptic surgery. An arthroscope was inserted into the palmar pouch of each MCP joint. Each joint was examined for inflammation and cartilage abnormalities. Photographs of each joint were taken at predetermined areas, so the same areas of cartilage, synovium and joint capsule were documented and scored within each joint. Following complete examination of each joint, synovial and cartilage biopsies were collected and the horses were recovered from general anesthesia. The synovial biopsy was placed in either 4% paraformaldehyde for later tissue embedding or snap frozen in liquid nitrogen for later mRNA isolation. Cartilage was also biopsied and processed in the same manner.
Effects of gene therapy on clinical parameters
Horses were examined for lameness on days -14, 0, 3, 7, 14, 21 and 28. All horses were observed at a walk and trot. Lameness was scored according to the 0-5 scale endorsed by the American Association of Equine Practitioners. 54 All joints were flexed and sensitivity to flexion recorded on a scale of 0 (no sensitivity) to 3 (high degree of sensitivity). Horses were then flexed for 10 s and trotted in a straight line. Lameness was scored and recorded again following flexion. Joint effusion was monitored by measuring joint circumference.
Digital photographs during arthroscopic examinations were scored for synovial hyperemia and thickening, cartilage softening (as assessed by indentation with a metal probe) and capsular inflammation. Scores between treatment groups were compared.
Effects of gene therapy on synovial fluid constituents
Synovial fluid drawn from all joints was analyzed for total and differential WBC count, protein concentration (Bradford dye binding assay) and hyaluronan content (Alcian-blue spectrophotometric assay). Values for all treatment groups were compared.
Effects of gene therapy on synovium and cartilage morphology
The synovial and cartilage biopsies were fixed in 4% paraformaldehyde for histology, immunohistochemistry and in situ hybridization. Fixed tissues were dehydrated in alcohol, embedded in paraffin and sectioned at 6 mm. The sections of synovium and cartilage were stained with hematoxylin and eosin to evaluate morphology, and the cartilage sections were stained with toluidine blue to assess proteoglycan content of the pericellular matrix. All synovial and cartilage scoring was performed by two observers unaware of treatment group. All scores were averaged between both observers. Synovium was evaluated by scoring the following parameters: villus architecture, villus subintimal fibrosis, intimal layer thickening, vasculature and inflammatory cell infiltrate. Scores from 0 (normal) to 3 (severe) were assigned to each category, and a composite score was derived. Cartilage was evaluated by scoring the following parameters: chondrocyte cloning, structure, cell type and toluidine blue staining. Similarly, scores from 0 to 3 were assigned to each category and a composite score Real-time quantitative PCR analysis of synovial membrane gene expression. Synovial tissue was homogenized, and mRNA was isolated according to the TriZol protocol (GIBCO-Life Technologies, Rockville, MD, USA). Insulin-like growth factor-I expression in synovium was assessed by PCR analysis of IGF-I message levels in RNA samples from synovium using the TaqMan s One-Step RT-PCR kit in a TaqMan s RealTime PCR (Applied Biosystems, Foster City, CA, USA). Primers and probes were designed using the known GenBank equine sequence utilizing the Primer Express Software (Applied Biosystems). Total copy numbers of RNA for IGF-I were measured from a validated standard curve. The IGF-I gene expression was normalized to 18S RNA expression. The mRNA levels in synovium before joint transduction and on day 35 after transduction were determined. The changes in IGF-I mRNA expression were then compared for all treatment groups.
In situ hybridization. Synovial and cartilage sections were prepared for hybridization using a modification of techniques described previously. 55 Equine-specific IGF-I riboprobes were generated from a 270-bp cDNA encoding exons 1-3 of equine IGF-IA precursor mRNA, corresponding to positions 1-270 of the available equine coding sequence (GenBank accession number U85272). Antisense and sense 35 S-labeled UTP (Perkin Elmer, Wellesley, MA, USA)-labeled riboprobes were transcribed on linearized templates. Sections were treated with proteinase K for 7 min to enhance probe entry. Tissue samples were hybridized with probes overnight at 431C in a humidified chamber. After incubation, samples were washed in 2 Â saline-sodium citrate (SSC)-0.5% 2-mercaptoethanol at 501C for 15 min, and 0.5 Â SSC-0.5% 2-mercaptoethanol at 501C for 1 h. Samples were then treated with RNase A (20 ml/ml) in 0.5 M NaCl-10 mM Tris (pH 7.5)-5 mM EDTA at 371C and washed in 2 Â SSC-50% formamide-0.5% 2-mercaptoethanol at 451C for 2 h. The slides were dehydrated through a graded series of alcohols containing 300 mM ammonium acetate, dried, dipped in NTB2 emulsion (Eastman Kodak, Rochester, NY, USA) and exposed for 21 days. The emulsion was developed in D-19 (Kodak), and sections were counterstained with hematoxylin and examined under bright-field and dark-field microscopy. All slides were processed in the same batch. Chamber slides coated with chondrocytes transfected with AdIGF-I served as positive control tissue, whereas negative control tissue consisted of untransfected chondrocytes. Scores were assigned to synovium harvested pretreatment and synovium retrieved arthroscopically on day 35. Scores were based on signal intensity and distribution and ranged from 0 to 3, with 0 equal to no signal and 3 equal to a large amount of silver grains distributed around many synoviocytes in the membrane. The differences in scores for all treatment groups were compared.
Effects of AdIGF-I transgene expression on cartilage Total proteoglycan. Total proteoglycan content of cartilage in each joint was assayed by the dimethylmethylene blue dye-binding spectrophotometric assay using 50 ml of papain-digested lyophilized tissue added to 2.5 ml dimethylmethylene blue solution (in formate buffer); the optical density was determined at 525 nm. 56 Mixed isomer shark chondroitin sulfate was used to construct the standard curve. Proteoglycan content of all treatment groups was compared.
In situ hybridization. Equine-specific type-IIB procollagen riboprobes were generated from a 201-bp cDNA encoding exons 1-7 of equine type-IIB procollagen mRNA corresponding to positions 138-339 of the available equine coding sequence (GenBank accession number U62528). The method was carried out in the same manner as described above for in situ hybridization of IGF-I in the synovium. Sections of costochondral junction and fetal epiphysis were used as controls. Each section received a score reflecting the level of probe hybridization, and scores for all treatment groups were compared.
Statistical analysis
Results were analyzed using a one-way analysis of variance for each continuous data set evolving from synovial fluid WBC count, IGF-I protein levels, hyaluronic acid levels and protein content of joint fluid, as well as the proteoglycan content of cartilage, and the mRNA levels in the synovium from each joint. Data from each test were determined to be normally distributed before performing each analysis. Significance was set at P-value p0.05. If significance was determined, a post hoc test of least squared differences was used for pairwise comparisons between groups.
Data resulting from clinical and arthroscopic examinations and scores from histological analysis were analyzed using a Kruskal-Wallis one-way analysis of variance for non-parametric data. A pairwise comparison of treatment group means was performed over all treatments to compare groups if a P-value p0.05 was obtained.
